Novozymes Biopharma is offering customers free evaluation samples of its Bacillus-based sodium hyaluronate, which is suitable for applications in the pharmaceutical and medical device sectors.
The company's sodium hyaluronate is 100 per cent free of animal-derived raw materials and organic solvent remnants.
The product is fermented using a non-pathogenic and well-documented production strain Bacillus subtilis, offering the medical device and pharmaceutical industries a range of benefits including increased safety, purity, batch-to-batch consistency and stability in large scale.
The company's sodium hyaluronate can be used in a range of applications in the pharmaceutical sector for improved drug discovery as well as in medical device application areas such as ophthalmology, dermatology, osteoarthritis, dermal fillers, adhesion prevention, coating and wound healing.
The sample programme precedes the 2011 launch of the Novozymes Biopharma's cGMP facility in Tianjin, China, and will provide an opportunity to experience the quality of the product, which will be manufactured at the cGMP Q7 validated site.
The samples are available to all companies interested in evaluating the cGMP Q7 product and can be applied for via a dedicated website.
